Narratek has been in the healthcare industry for over 25 years -- providing: consulting, expert witnessing, medical-reporting products, medical-device development and marketing, wellness services, and software programs. In light of the overwhelming pandemic threat, the company has transitioned its focus to help bring needed products and guidance to the fight against SARS-CoV-2, the coronavirus that causes COVID-19.
Narratek's CEO is Joe Weber. During his several decades in the healthcare industry, Joe has been engaged in medical research, hospital administration, consulting, and marketing. He has published and presented extensively on a variety of healthcare topics, mostly related to electronic health records. He has been CEO or VP/Marketing for health systems and medical device companies, having served as Associate Director for Ambulatory Care at Cook County Hospital very early in his career. Joe is the holder of 3 U.S. patents, including the invention of predictive typing, also known as automatic word completion (Patent No. 5,305,205, filed in 1990). This was recognized as one of the 56 most important innovations to come out of Massachusetts along with: the telephone, Internet, first college, Facebook, anesthesia, etc. Exhibited at Boston's Logan Airport: https://www.linkedin.com/pulse/invention-predictive-typing-joe-weber/ Joe has a BA in Biology from Brandeis, an MS in Biostatistics from Columbia, and an MS in Management from M.I.T.
Joe is also President of NevCare USA. NevCare is headquartered in Australia.
Additional background about Joe on LinkedIn: https://www.linkedin.com/in/joe-weber-327b9a6/
We have been advocating for strategies that will help in this war against the pandemic. For example, here is our suggestion (submitted to the CDC) about how data can become a powerful weapon for combatting such a formidible and elusive enemy:
There is considerable variation in how infection by this coronavirus affects individuals. We know that age, sex, race, and comorbidities impact clinical outcomes. But we do not know much else. If everyone tested for COVID-19 filled out a brief online questionnaire before having either a molecular or antibody test, we could potentially learn what influences the range of response. They would document their demographics and any symptoms to date, along with the other data that might be correlated to disease severity. The key variables are medications, nutritional supplements, and vaccinations, which – unlike demographics – an individual can control.
We would then track any clinical interventions and the eventual outcome. Perhaps, after controlling for relevant demographics, we find that there is a high correlation between daily fish oil capsules and minimal symptoms in those that test positive for having the disease. Or maybe it’s an inverse relationship. Or no relationship. Whatever the result, it will be publicized, so everyone can benefit from that knowledge. Even invisible threats can often be effectively managed with data analytics.